Large-cap pharmaceutical stocks have spent much of the year under investor scrutiny as markets price in looming patent expirations on core therapies. Much of that anxiety centers on the scheduled 2028 loss of exclusivity for Keytruda, the oncology drug that remains the company’s largest seller. That broader unease has weighed on peers such as Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE).
Merck & Co. (NYSE:MRK), however, has diverged noticeably from sector pessimism. The stock has advanced 42.3% since January and is trading near $146.73, reflecting investor willingness to separate headline patent risk from the company’s operating trajectory.
Third-quarter results and management actions
Merck’s third-quarter financials helped explain why institutional capital has supported the shares. The company reported revenue of $18.1 billion, above consensus expectations of $17.28 billion, and adjusted earnings per share of $2.49 compared with a $2.09 consensus. Those results prompted management to raise full-year 2026 revenue guidance to a range of $66.8 billion to $67.3 billion.
Keytruda sales expanded 6% year-over-year to $8.6 billion in the quarter. More important, Merck is actively reshaping the commercial lifecycle for the franchise. A subcutaneous formulation of Keytruda, administered by injection instead of prolonged intravenous infusion, is designed to extend patent protections well into the 2030s. Management has set a conversion goal of 30% to 40% of U.S. patients on Keytruda Qlex by the end of 2027, an approach that management says will soften what otherwise might have been an abrupt revenue cliff.
New and growing products
Other launches are accelerating alongside Keytruda’s reformulation. Winrevair, a therapy for pulmonary arterial hypertension, rose 94% year-over-year to $694 million in the quarter, supported by an expanded FDA label that enables earlier clinical intervention. In oncology, the personalized cancer vaccine intismeran, developed in partnership with Moderna, demonstrated a 42% reduction in the risk of melanoma recurrence or death when given with Keytruda in Phase 3 trials; Merck plans a regulatory filing for intismeran in 2027.
On the back of these programs, management projects consolidated revenues to exceed $70 billion by the mid-2030s.
Cash flow, capital returns and balance-sheet signals
Merck’s operating performance is supported by substantial liquidity. The company generated $18.7 billion in operating cash flow over the trailing twelve months, which yields a 4.07% free cash flow return that covers its 2.31% dividend yield. Merck has raised its dividend for 15 consecutive years and plans roughly $3 billion of share repurchases for 2026. InvestingPro’s Financial Health framework rates Merck as "Good," citing dependable cash flow coverage for debt service.
Valuation and Wall Street positioning
The stock currently trades at a headline multiple of 52.2 times trailing earnings, a figure that reflects a trough year in reported accounting profits. Consensus estimates compiled on InvestingPro indicate the multiple compressing to 16.3 times projected 2027 earnings. Management acknowledges more than $2 billion of expected 2027 revenue headwinds from legacy generic competition, but points to the pipeline as a substantive offset to those pressures.
Analysts remain broadly constructive. The median price target sits at $161.53, implying double-digit upside from current levels. Higher targets from top-tier firms include $175 from JPMorgan and $174 from Morgan Stanley following the third-quarter results.
How market positioning transformed perceived risk
Merck’s performance this year illustrates that patent expirations do not invariably produce sudden, company-wide declines when management can deploy strategic formulation changes, advance new approvals and sustain operating cash generation. The company has effectively converted an expected revenue cliff into an extended transition through a combination of subcutaneous delivery development, new product launches, and stable cash flow.
InvestingPro’s ProPicks AI models added Merck to the Dominate the Dow strategy in January at $103.13. In the November active portfolio, Merck is included alongside other resilient large-cap names spanning industrial power generation, oncology biopharma development, and national telecom services. Subscribers are offered access to portfolio allocations and research within the InvestingPro platform.
Conclusion
By pairing product reformulation and new therapy momentum with strong cash conversion and a track record of capital returns, Merck has navigated patent-related market concerns and delivered sizable share-price appreciation year-to-date. The company’s third-quarter beat, raised guidance, pipeline progress and cash-generation profile underpin an investment case that has persuaded both institutional portfolios and sell-side analysts to maintain constructive views.
Data and financial metrics cited here are reported as of November 10, 2026.